[go: up one dir, main page]

NO954168L - Indolderivater som 5-HT1-lignende agonister for anvendelse mot migrene - Google Patents

Indolderivater som 5-HT1-lignende agonister for anvendelse mot migrene

Info

Publication number
NO954168L
NO954168L NO954168A NO954168A NO954168L NO 954168 L NO954168 L NO 954168L NO 954168 A NO954168 A NO 954168A NO 954168 A NO954168 A NO 954168A NO 954168 L NO954168 L NO 954168L
Authority
NO
Norway
Prior art keywords
alkyl
migraine
agonists
optionally
aryl
Prior art date
Application number
NO954168A
Other languages
English (en)
Other versions
NO954168D0 (no
Inventor
Martin James Wythes
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939308360A external-priority patent/GB9308360D0/en
Priority claimed from GB939324433A external-priority patent/GB9324433D0/en
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of NO954168D0 publication Critical patent/NO954168D0/no
Publication of NO954168L publication Critical patent/NO954168L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forbindelser med formel (I): farmasøytisk akseptable salter derav, og farmasøytisk akseptable solvater (inklusive hydrater) av hver entitet, hvor R1 er (A); (B); (C); (D) ; .R3 (A) (C) p (B) (D) eller CH2CH2NR3R< (E); R2 er R5R6C(OH)A eller R7COA; R3 er H, Ci-Cjalkyl, substituert alkylen, C3-C7cykloalkyl eventuelt substituert med HO, C3-C6alkenyl eventuelt substituert med aryl, C5-C7cykloalkenyl eller C3-C6- alkynyl; R4 er H eller (VCjalkyl; Rs og R* er hver uavhengig valgt fra H, C^-Cjalkyl, C^-C, perfluoralkyl og C3-C7cykloalkyl, eller sammen med karbonatomet som de er knyttet til, danner de en 3- til 7-leddet karbocyklisk eller eventuell heterocyklisk ring; R7 er Ci-Cjalkyl, substituert alkylen, C3-C7cykloalkyl eller aryl; A er en direkte binding eller eventuelt -forgrenet CVCjalkylen eller C2-C6alkenylen; og k er O, l eller 2; er selektive 5-HTj-lignende agonister som er nyttige ved behandling av migrene; migrenelignede hodepine, kronisk paroksysmal hemikrani og hodepine forbundet med vaskulære forstyrrelser.
NO954168A 1993-04-22 1995-10-19 Indolderivater som 5-HT1-lignende agonister for anvendelse mot migrene NO954168L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939308360A GB9308360D0 (en) 1993-04-22 1993-04-22 Indoles
GB939324433A GB9324433D0 (en) 1993-11-27 1993-11-27 Indoles
PCT/EP1994/001121 WO1994024127A1 (en) 1993-04-22 1994-04-11 Indole derivatives as 5-h1-like agonists for use in migraine

Publications (2)

Publication Number Publication Date
NO954168D0 NO954168D0 (no) 1995-10-19
NO954168L true NO954168L (no) 1995-10-19

Family

ID=26302791

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954168A NO954168L (no) 1993-04-22 1995-10-19 Indolderivater som 5-HT1-lignende agonister for anvendelse mot migrene

Country Status (21)

Country Link
US (1) US5607960A (no)
EP (1) EP0695301B1 (no)
JP (1) JP2802169B2 (no)
KR (1) KR960701865A (no)
CN (1) CN1121348A (no)
AT (1) ATE144773T1 (no)
AU (1) AU6567094A (no)
BR (1) BR9406481A (no)
CA (1) CA2157397C (no)
CZ (1) CZ274595A3 (no)
DE (1) DE69400824T2 (no)
DK (1) DK0695301T3 (no)
ES (1) ES2094653T3 (no)
FI (1) FI954944A7 (no)
GR (1) GR3021804T3 (no)
HU (1) HUT73807A (no)
IL (1) IL109337A0 (no)
NO (1) NO954168L (no)
NZ (1) NZ265269A (no)
PL (1) PL311204A1 (no)
WO (1) WO1994024127A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
WO1995006636A1 (en) * 1993-08-31 1995-03-09 Pfizer Inc. 5-arylindole derivatives
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9420503D0 (en) * 1994-10-11 1994-11-23 Pfizer Ltd Therapeutic agents
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
KR19980703048A (ko) * 1995-03-20 1998-09-05 피터쥐.스트링거 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1ｈ-인돌: 신규한 5-ｈｔ1ｆ 아고니스트
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
AU4074897A (en) * 1996-09-18 1998-04-14 Eli Lilly And Company A method for the prevention of migraine
ES2208955T3 (es) * 1996-11-26 2004-06-16 Nps Allelix Corp. Compuestos 5-ciclo-indolicos como ligandos del receptor 5-ht1d.
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
US5856510A (en) * 1996-12-16 1999-01-05 Allelix Biopharmaceuticals Inc. 5-alkenyl and 5-alkynyl indole compounds
GB9705035D0 (en) * 1997-03-11 1997-04-30 Pharmacia & Upjohn Spa Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation
EP0875513A1 (en) * 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
CA2299286A1 (en) * 1997-08-09 1999-02-18 Laramie Mary Gaster Bicyclic compounds as ligands for 5-ht1 receptors
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6204274B1 (en) 1998-04-29 2001-03-20 American Home Products Corporation Indolyl derivatives as serotonergic agents
US6066637A (en) * 1998-06-19 2000-05-23 American Home Products Corporation Indolyl derivatives as serotonergic agents
AU4961499A (en) * 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
KR100851793B1 (ko) * 2000-07-21 2008-08-13 하. 룬트벡 아크티에 셀스카브 Ｃｎｓ 장애의 치료에 유용한 인돌 유도체
US6489512B1 (en) 2002-06-21 2002-12-03 Rhodia Chirex Inc. Method for making aryl hydrazines and substituted indoles
BR0317126A (pt) * 2002-12-10 2005-10-25 Merck Patent Gmbh Derivados de indol e o uso dos mesmos como ligantes de 5-ht
AU2003299227A1 (en) * 2002-12-20 2004-07-14 Ciba Specialty Chemicals Holding Inc. Synthesis of amines and intermediates for the synthesis thereof
PT1575566E (pt) * 2002-12-26 2012-03-29 Pozen Inc Formas de dosagem em multicamada contendo naproxeno e triptanos
BRPI0410807A (pt) * 2003-06-06 2006-06-27 Glaxo Group Ltd composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
WO2005066157A1 (en) * 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators
GB0807772D0 (en) * 2008-04-29 2008-06-04 Lectus Therapeutics Ltd Calcium ion modulators and uses thereof
FR2953720B1 (fr) * 2009-12-11 2012-05-11 Oreal Utilisation de derives de benzyloxy-ethylamines comme conservateur,
CN104557957B (zh) * 2013-10-09 2017-04-19 华东师范大学 螺‑氧化吲哚环氧乙烷衍生物的合成方法
JP2023512821A (ja) * 2020-02-04 2023-03-29 マインドセット ファーマ インコーポレイテッド 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体
CN119698412A (zh) * 2023-07-24 2025-03-25 上海翊石医药科技有限公司 一类5-ht2a受体激动剂及其制备方法和应用
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8530507D0 (en) * 1985-12-11 1986-01-22 Glaxo Group Plc Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
HUT64326A (en) * 1990-10-15 1993-12-28 Pfizer Process for production indole derivatives and pharmaceutical preparations containing these compounds

Also Published As

Publication number Publication date
GR3021804T3 (en) 1997-02-28
CA2157397A1 (en) 1994-10-27
ATE144773T1 (de) 1996-11-15
AU6567094A (en) 1994-11-08
NZ265269A (en) 1996-09-25
FI954944A0 (fi) 1995-10-17
DE69400824D1 (de) 1996-12-05
DE69400824T2 (de) 1997-03-13
KR960701865A (ko) 1996-03-28
HU9501920D0 (en) 1995-09-28
NO954168D0 (no) 1995-10-19
CZ274595A3 (en) 1996-03-13
DK0695301T3 (da) 1996-12-09
IL109337A0 (en) 1994-07-31
JPH08507083A (ja) 1996-07-30
EP0695301B1 (en) 1996-10-30
EP0695301A1 (en) 1996-02-07
PL311204A1 (en) 1996-02-05
US5607960A (en) 1997-03-04
CN1121348A (zh) 1996-04-24
BR9406481A (pt) 1996-01-09
CA2157397C (en) 1999-07-06
ES2094653T3 (es) 1997-01-16
FI954944A7 (fi) 1995-10-17
WO1994024127A1 (en) 1994-10-27
HUT73807A (en) 1996-09-30
JP2802169B2 (ja) 1998-09-24

Similar Documents

Publication Publication Date Title
NO954168L (no) Indolderivater som 5-HT1-lignende agonister for anvendelse mot migrene
DE3882614D1 (de) Indol-derivate.
DK391289A (da) Indolderivater
YU108791A (sh) Pirazolopirimidinon antianginalna jedinjenja
EP1288199A4 (en) INHIBITORS OF MMP-12
DE69132713D1 (de) Benzylidenthiazolidinderivate, ihre Herstellung und ihre Anwendung als Lipidperoxid-Inhibitoren
ATE104145T1 (de) 4-substituierten imidazolen zur senkung des intraokularen druckes.
DK0785933T3 (da) Indolderivater som 5HT1-lignende agonister
CA2192596A1 (en) 4-(6-fluoro-1,2-benzisoxazolyl)-1-piperidinyl-propoxy-chromen-4-one derivatives, their preparation and their use in the treatment of psychosis, schizophrenia and anxiety
MY103509A (en) Indole derivatives.
FI970397L (fi) Substituoituja 1,4-dihydroksylopent(b)indol-3(2H)-onijohdannaisia
CA2202348A1 (en) Indole derivatives as 5ht1-like agonists